Iktos announced research alliance with Almirall for new drug design
By Nikita Chaurasia  Date: 2019-12-14

Iktos announced research alliance with Almirall for new drug design
  • The new drug design to involve AI technology for optimization of advanced compounds and boosting up the identification if drug candidates for Almirall drug discovery program.
  • The agreement is likely to provide rapid identification of molecules for the satisfaction of multiple bioactivity for clinical trials.
  • Under the pact, Almirall would leverage Iktos’s AI accuracy to bring about a difference in the patients’ lives.

One of the prominent AI companies dealing in novel drug design, Iktos, has reportedly announced establishing a research partnership with leading skin-health focused pharmaceutical company, Almirall on the grounds of designing novel drug compounds via the use of Iktos’ AI technology.

As per reliable reports, Iktos’ AI technology offers high speed and efficiency to the drug discovery process through automatically designing virtual molecules that display desirable characteristics of an advanced drug candidate. This is apprehended to tacked one of the fundamental challenges in drug design which is the rapid and repetitive identification of molecules that authenticate the multiple bioactive attributes for testing.

On this acquisition, the executive Vice president R&D and Chief Scientific Officer of Almirall, Dr. Bhushan Hardas was quoted stating that the collaboration serves as an example of how the company intends to explore myriad possibilities served by the technology to discover new molecules and boost the clinical development. He further added that the company has planned to stand at the forefront of innovations to build holistic and transversal approaches in the medical field. AI is anticipated to offer Almirall a distinctive opportunity to amalgamate its skills with an intent to augmenting patients’ lives.

Meanwhile, the president and CEO of Iktos, Yann Gaston- Mathe, cited that the company is delighted to be partnered with Almirall as this collaboration would bolster the leadership position of the company in the domain of AI for new drug design. 

Iktos has of late announced umpteen collaborations and mergers with the biopharmaceutical companies where the company lays immense focus on accelerating the design of promising compounds.

Source credit: https://finance.yahoo.com/news/iktos-almirall-announce-research-collaboration-080100761.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Fragomen acquires SimpleCitizen to reinforce its immigration services
Fragomen acquires SimpleCitizen to reinforce its immigration services
By Nikita Chaurasia

In a recent turn of events, Fragomen, Del Rey, Bernsen & Loewy, LLP, a leading corporate immigration law company has reportedly joined hands with SimpleCitizen Inc. to form Fragomen Technologies Inc., a new subsidiary which will provide a combina...

Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
Nautilus buys 17 MW portfolio from solar energy developer Pine Gate
By Nikita Chaurasia

Solar project development and asset management major, Nautilus Solar Energy LLC, has reportedly announced its acquisition of two solar portfolios in Rhode Island and Oregon amounting to a total of nearly 17 MW from leading solar energy developer, Pin...

Locate Bio obtains multiple late stage orthobiologics assets from RCSI
Locate Bio obtains multiple late stage orthobiologics assets from RCSI
By Nikita Chaurasia

Regenerative medicine major, Locate Bio, has reportedly announced its in-licensing of several late stage orthobiologics assets from the RCSI University of Medicine and Health Sciences. Sources state that the technologies created by the RCSI Tissue E...

Roche acquires Inflazome to gain control over inflammatory treatments
Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million). As per the agreement, Roche will acquire complete rights ...

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Soci...